Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial (Ann Oncol (2019) 30 (1992–2003) (5574397)(10.1093/annonc/mdz396))

the STAMPEDE investigators

Research output: Contribution to journalComment/debate

13 Downloads (Pure)

Abstract

The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.

Original languageEnglish
Number of pages1
JournalAnnals of Oncology
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial (Ann Oncol (2019) 30 (1992–2003) (5574397)(10.1093/annonc/mdz396))'. Together they form a unique fingerprint.

  • Cite this